- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
 |
109431-87-0
C9H17NO3
187.24
1.142
98.0% min (HPLC); 99.0% min (Chiral)
White to off-white solid
Cholangiocarcinoma
Futibatinib
11/05/2039 (Futibatinib)
FGFR
Y
5 t
2020
ISO 9001;ISO 14001;ISO 45001
Supply Chain
As of August 19, 2024, there are 171 potential suppliers manufacturing Futibatinib intermediate (R)-1-N-Boc-3-hydroxypyrrolidine (CAS No. 109431-87-0), including 112 factories and 35 labs, among which:
- The 25th percentile has an average registered capital of 1 million CNY;
- The 50th percentile has an average registerd capital of 3 million CNY;
- The 75th percentile has an average registered capital of 10 million CNY.
Feeling overwhelmed? Contact Unibest if you need us to quality-check other sources to strengthen your supply chain or to find a tailored solution for your specific procurement request.
Usage and ROS Analysis
Structure of Futibatinib
There are three distinct moieties of Futibatinib:
a pyrrolidine
a pyrazolo[3,4-d]pyrimidine
1-ethynyl-3,5-dimethoxybenzene
From the above synthesis map, the three key moieties correspond to the following Futibatinib intermediates
a pyrrolidine: CAS No. 109431-87-0
a pyrazolo[3,4-d]pyrimidine: CAS No. 151266-23-8
1-ethynyl-3,5-dimethoxybenzene: CAS No. 171290-52-1
For this particular Futibatinib intermediate, tert-butyl (3R)-3-hydroxypyrrolidine-1-carboxylate, CAS No. 109431-87-0, the chiral center is to be conjugated with the secondary amine on the 1H-pyrazole from the pyrazolo[3,4-d]pyrimidine moeity.
Recommended Source
Unibest has identified few sources that can supply these Futibatinib intermediates, and their capacity can reach up to tons.
This particular Futibatinib intermediate, tert-butyl (3R)-3-hydroxypyrrolidine-1-carboxylate, CAS No. 109431-87-0, has a wide synthetic application in pharmaceuticals and it was orginally developed by our partner for a phase III new drug for breast cancer.
